Bicycle Therapeutics
BCYC
101 hedge funds and large institutions have $1.31B invested in Bicycle Therapeutics in 2021 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 12 closing their positions.
275% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 12
122% more capital invested
Capital invested by funds: $591M → $1.31B (+$721M)
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
69% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $1.56M
46% more funds holding
Funds holding: 69 → 101 (+32)
17.65% more ownership
Funds ownership: 55.71% → 73.35% (+18%)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.1M |
| 2 |
RI
RTW Investments
New York
|
+$48M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43.9M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$31.5M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$33.4M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$28.6M |
| 3 |
AVA
Atlas Venture Advisors
Boston,
Massachusetts
|
-$12.8M |
| 4 |
SC
Samlyn Capital
New York
|
-$8.04M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$4.16M |
BCYC Hedge Fund Activity: Q4 2021 in Review
101 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q4 2021, worth a combined $1.31B — up 122% from $591M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BCYC positions and 12 closed out — a net gain of 33 holders — while 26 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $55.1M. The largest seller was Logos Global Management, cutting an estimated $33.4M.
- 101 institutional investors held Bicycle Therapeutics (BCYC) as of Q4 2021, up from 69 in Q3 2021.
- Funds reported $1.31B of Bicycle Therapeutics stock for Q4 2021, up 122% quarter-over-quarter.
- 45 funds opened new Bicycle Therapeutics positions in Q4 2021 and 12 closed out, a net change of +33 holders.
- The largest Bicycle Therapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $55.1M added.
- The largest Bicycle Therapeutics seller in Q4 2021 was Logos Global Management, an estimated $33.4M sold.
Based on aggregated 13F filings for Q4 2021.